Cytotoxic effects of chemotherapy on cancer and immune cells: How can it be modulated to generate novel therapeutic strategies?

Future Oncology

Volumn 11, Issue 19, 2015, Pages 2645-2654

  Rébé, Cédric ^a,b   Ghiringhelli, François ^a,b,c  

^a INSERM   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

cancer; chemotherapy; immune cells

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE;

ADAPTIVE IMMUNITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; CELL KILLING; DRUG CYTOTOXICITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

EID: 84943794874     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.198     Document Type: Article

References (63)

1. Schmetzer O, Florcken A. Sex differences in the drug therapy for oncologic diseases. Handb. Exp. Pharmacol. 214, 411-442 (2012
2. Verzoni E, De Braud F, Fabiani F, Grassi P, Testa I, Procopio G. Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. Future Oncol. 9(11), 1599-1607 (2013
3. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect. Immun. 73(4), 1907-1916 (2005
4. Galluzzi L, Vitale I, Abrams JM., et al. Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012. Cell Death Differ. 19(1), 107-120 (2012
5. Lake RA, Robinson BW. Immunotherapy and chemotherapy-A practical partnership. Nat. Rev. Cancer 5(5), 397-405 (2005
6. Martins I, Wang Y, Michaud M., et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 21(1), 79-91 (2014
7. Youn JH, Shin JS. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol. 177(11), 7889-7897 (2006
8. Bonaldi T, Talamo F, Scaffidi P., et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22(20), 5551-5560 (2003
9. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9(5), 353-363 (2009
10. Ladoire S, Hannani D, Vetizou M., et al. Cell-death-Associated molecular patterns as determinants of cancer immunogenicity. Antioxid. Redox. Signal. 20(7), 1098-1116 (2014
11. Martins I, Kepp O, Schlemmer F., et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30(10), 1147-1158 (2011
12. Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. Annu. Rev. Pathol. 10, 173-194 (2015
13. Chao MP, Jaiswal S, Weissman-Tsukamoto R., et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med. 2(63), 63ra94 (2010
14. Kepp O, Senovilla L, Vitale I., et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3(9), e955691 (2014
15. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51-72 (2013
16. Vacchelli E, Aranda F, Eggermont A., et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 3(1), e27878 (2014
17. Nowak AK, Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv. Drug Deliv. Rev. 58(8), 975-990 (2006
18. Zhang L, Dermawan K, Jin M., et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin. Immunol. 129(2), 219-229 (2008
19. Ghiringhelli F, Larmonier N, Schmitt E., et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34(2), 336-344 (2004
20. Beyer M, Kochanek M, Darabi K., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106(6), 2018-2025 (2005
21. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 70(12), 4850-4858 (2010
22. Ladoire S, Mignot G, Dabakuyo S., et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J. Pathol. 224(3), 389-400 (2011
23. Antonopoulos C, El Sanadi C, Kaiser WJ, Mocarski ES, Dubyak GR. Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1β via caspase-8 in dendritic cells. J. Immunol. 191(9), 4789-4803 (2013
24. Wehner R, Bitterlich A, Meyer N., et al. Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cells. Int. J. Cancer 132(6), 1351-1359 (2013
25. Bugaut H, Bruchard M, Berger H., et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS ONE 8(6), e65181 (2013
26. Chen J, Huang X, Huang G, Chen Y, Chen L, Song H. Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. Cancer Biother. Radiopharm. 27(3), 210-220 (2012
27. Vincent J, Mignot G, Chalmin F., et al. 5-fluorouracil selectively kills tumor-Associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8), 3052-3061 (2010
28. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16(18), 4583-4594 (2010
29. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011
30. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunitys roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011
31. Apetoh L, Ghiringhelli F, Tesniere A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050-1059 (2007
32. Tesniere A, Schlemmer F, Boige V., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4), 482-491 (2010
33. Ghiringhelli F, Apetoh L, Tesniere A., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15(10), 1170-1178 (2009
34. Menger L, Vacchelli E, Adjemian S., et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci. Transl. Med. 4(143), 143ra199 (2012
35. Kepp O, Semeraro M, Bravo-San Pedro JM., et al. eIF2α phosphorylation as a biomarker of immunogenic cell death. Semin. Cancer Biol. doi:10.1016/j.semcancer.2015.02.004 (2015) (Epub ahead of print
36. Kepp O, Menger L, Vacchelli E., et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev. 24(4), 311-318 (2013
37. Ghiringhelli F, Bruchard M, Chalmin F, Rebe C. Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J. Biomed. Biotechnol. 473712 (2012
38. Yamazaki T, Hannani D, Poirier-Colame V., et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 21(1), 69-78 (2014
39. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM. Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J. Immunol. 167(2), 623-627 (2001
40. Crawford MA, Burdick MD, Glomski IJ., et al. Interferon-inducible CXC chemokines directly contribute to host defense against inhalational anthrax in a murine model of infection. PLoS Pathog. 6(11), e1001199 (2010
41. Dyer KD, Percopo CM, Fischer ER, Gabryszewski SJ, Rosenberg HF. Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood 114(13), 2649-2656 (2009
42. Sistigu A, Yamazaki T, Vacchelli E., et al. Cancer cell-Autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20(11), 1301-1309 (2014
43. Schneider H, Rudd CE. Diverse mechanisms regulate the surface expression of immunotherapeutic target CTLA-4. Front. Immunol. 5, 619 (2014
44. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33(17), 1974-1982 (2015
45. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr. Opin. Pharmacol. 23, 32-38 (2015
46. Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin. Immunol. 153(1), 145-152 (2014
47. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1), 111-122 (2007
48. Arce F, Kochan G, Breckpot K, Stephenson H, Escors D. Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy. Anticancer Agents Med. Chem. 12(1), 29-39 (2012
49. Galluzzi L, Vacchelli E, Bravo-San Pedro JM., et al. Classification of current anticancer immunotherapies. Oncotarget 5(24), 12472-12508 (2014
50. Vegran F, Berger H, Boidot R., et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat. Immunol. 15(8), 758-766 (2014
51. Zeng R, Spolski R, Finkelstein SE., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201(1), 139-148 (2005
52. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu. Rev. Immunol. 32, 189-225 (2014
53. Dincalci M. Trabectedin mechanism of action: whats new? Future Oncol. 9(Suppl 12), 5-10 (2013
54. Bruchard M, Mignot G, Derangere V., et al. Chemotherapy-Triggered cathepsin B release in myeloid-derived suppressor cells activates the NLRP3 inflammasome and promotes tumor growth. Nat. Med. 19(1), 57-64 (2013
55. Heusinkveld M, Van Der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 9, 216 (2011
56. Bryniarski K, Szczepanik M, Ptak M, Zemelka M, Ptak W. Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. Pharmacol. Rep. 61(3), 550-557 (2009
57. Buhtoiarov IN, Sondel PM, Wigginton JM., et al. Anti-Tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CPG-ODN immunotherapy through repolarization of tumour-Associated macrophages. Immunology 132(2), 226-239 (2011
58. Bracci L, Moschella F, Sestili P., et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13(2 Pt 1), 644-653 (2007
59. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65(8), 3437-3446 (2005
60. Viaud S, Saccheri F, Mignot G., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342(6161), 971-976 (2013
61. Iida N, Dzutsev A, Stewart CA., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342(6161), 967-970 (2013
62. Garrett WS. Cancer and the microbiota. Science 348(6230), 80-86 (2015
63. Wu P, Wu D, Ni C., et al. GammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40(5), 785-800 (2014